Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3161388 | 0.93 | PDK2 (0.46) | PDK2KDM4EALDH1A1MTNR1AMTNR1B | |
| SCHEMBL3174370 | 0.82 | PDK2 (0.45) | PDK2KDM4EALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL188371 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2LTA4HCHRNB2 | |
| SCHEMBL3170270 | 0.78 | PDK2 (0.46) | PDK2SMN1; SMN2LTA4H | |
| SCHEMBL1419119 | 0.77 | LTA4H (0.54) | KDM4EALDH1A1LTA4HCHRNB2CHRNA4 | |
| SCHEMBL3154702 | 0.77 | PDK2 (0.45) | PDK2SMN1; SMN2LTA4H | |
| SCHEMBL9851861 | 0.76 | ALDH1A1 (0.51) | KDM4EALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL3161487 | 0.76 | THRB (0.41) | KDM4EALDH1A1SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL1283116 | 0.76 | KDM4E (0.49) | KDM4E | |
| SCHEMBL3154717 | 0.75 | L3MBTL1 (0.68) | PDK2ALDH1A1MTNR1AMTNR1BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1630165-B1 | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1630165-A1 | [1,2,4 ]TRIAZOLO [1,5-A]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | PDK2 1705/4885KDM4E 2344/4885ALDH1A1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.